[EGRX] Eagle Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 730.08 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 80.93 Change: 5.35 (7.08%)
Ext. hours: Change: 0 (0%)

chart EGRX

Refresh chart

Strongest Trends Summary For EGRX

EGRX is in the medium-term up 49% in 1 year. In the long-term down -37% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was found

Fundamental Ratios
Shares Outstanding15.64 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 526.88% Sales Growth - Q/Q548.38% P/E
P/E To EPS Growth P/S14.45 P/BV7.1 Price/Cash Per Share
Price/Free Cash Flow-52.57 ROA1.66% ROE2.09% ROI
Current Ratio4.8 Quick Ratio4.72 Long Term Debt/Equity Debt Ratio0.26
Gross Margin71.95% Operating Margin2.84% Net Profit Margin4.26% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities55.29 M Cash From Investing Activities3.95 M Cash From Operating Activities17.96 M Gross Profit30.36 M
Net Profit19.7 M Operating Profit20.09 M Total Assets129.93 M Total Current Assets129.79 M
Total Current Liabilities27.05 M Total Debt Total Liabilities27.05 M Total Revenue36.31 M
Technical Data
High 52 week81.63 Low 52 week36.72 Last close56.99 Last change0.11%
RSI59.11 Average true range2.7 Beta1.25 Volume253.51 K
Simple moving average 20 days3.75% Simple moving average 50 days5.1% Simple moving average 200 days15.75%
Performance Data
Performance Week6.5% Performance Month5.75% Performance Quart-0.63% Performance Half44.39%
Performance Year-27.44% Performance Year-to-date41.45% Volatility daily1.88% Volatility weekly4.21%
Volatility monthly8.64% Volatility yearly29.92% Relative Volume311.49% Average Volume155.02 K
New High New Low

News

2019-09-10 07:29:32 | Does The Eagle Pharmaceuticals, Inc. NASDAQ:EGRX Share Price Tend To Follow The Market?

2019-09-04 08:40:12 | Insulet PODD Catches Eye: Stock Jumps 8.9%

2019-08-28 16:30:00 | Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference

2019-08-20 16:47:08 | Nabriva NBRV Gains FDA Approval for Pneumonia Drug Xenleta

2019-08-18 10:21:44 | Should Eagle Pharmaceuticals, Inc. NASDAQ:EGRX Be Your Next Stock Pick?

2019-08-14 10:29:02 | New Strong Buy Stocks for August 14th

2019-08-11 12:29:42 | Edited Transcript of EGRX earnings conference call or presentation 8-Aug-19 12:30pm GMT

2019-08-09 06:23:49 | Eagle Pharmaceuticals Inc EGRX Q2 2019 Earnings Call Transcript

2019-08-08 08:45:12 | Eagle Pharmaceuticals EGRX Beats Q2 Earnings and Revenue Estimates

2019-08-08 06:50:00 | Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results

2019-08-05 06:50:00 | Eagle Pharmaceuticals Announces Clinical Development Plan of Innovative Product Intended to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor ER-Positive Breast Cancer

2019-08-01 10:33:02 | Earnings Preview: Eagle Pharmaceuticals EGRX Q2 Earnings Expected to Decline

2019-07-29 16:30:00 | Eagle Pharmaceuticals to Discuss Second Quarter 2019 Financial Results on August 8, 2019

2019-07-26 07:54:59 | Is Eagle Pharmaceuticals NASDAQ:EGRX Using Too Much Debt?

2019-07-03 13:59:00 | Should You Worry About Eagle Pharmaceuticals, Inc.'s NASDAQ:EGRX CEO Pay Cheque?

2019-07-03 08:48:00 | Park Service diverts $2.5 million in fees to pay for Trump’s July 4th celebration | Beto O’Rourke says he’s unaware of his fundraising numbers

2019-06-15 08:05:07 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-06-13 08:02:18 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-06-11 08:02:57 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-06-10 08:05:21 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-06-06 08:05:01 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-06-04 08:05:13 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-05-31 15:07:47 | Here's Why I Think Eagle Pharmaceuticals NASDAQ:EGRX Might Deserve Your Attention Today

2019-05-28 16:30:00 | Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference

2019-05-15 16:30:00 | Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference

2019-05-09 20:43:25 | Hedge Funds Have Never Been More Bullish On Eagle Pharmaceuticals Inc EGRX

2019-05-08 06:00:00 | Can Eagle Pharma Fly through its Oncology Trials

2019-05-07 17:50:27 | Edited Transcript of EGRX earnings conference call or presentation 7-May-19 12:30pm GMT

2019-05-07 12:23:21 | Eagle Pharmaceuticals Inc EGRX Q1 2019 Earnings Call Transcript

2019-05-07 08:05:12 | Eagle Pharmaceuticals EGRX Beats Q1 Earnings and Revenue Estimates

2019-05-07 08:04:35 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-05-07 07:04:52 | Did You Miss Eagle Pharmaceuticals's NASDAQ:EGRX Whopping 457% Share Price Gain?

2019-05-07 06:58:29 | Eagle Pharmaceuticals: 1Q Earnings Snapshot

2019-05-07 06:50:00 | Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results

2019-05-07 06:45:00 | Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure

2019-04-30 10:32:02 | Eagle Pharmaceuticals EGRX Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2019-04-30 08:04:49 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-04-29 06:50:00 | Eagle Pharmaceuticals to Discuss First Quarter 2019 Financial Results on May 7, 2019

2019-04-22 09:48:01 | New Strong Sell Stocks for April 22nd

2019-04-22 06:50:00 | CMS Establishes Unique J-Code for BELRAPZO™ Bendamustine 500mL Hydrochloride Injection

2019-04-15 06:50:00 | Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA™ with Teva Pharmaceuticals International GmbH

2019-04-09 10:48:39 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-04-03 14:09:35 | Don't Sell Eagle Pharmaceuticals, Inc. NASDAQ:EGRX Before You Read This

2019-04-02 11:52:41 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-03-28 07:35:00 | Consolidated Research: 2019 Summary Expectations for Penn National Gaming, Nomad Foods, Americold Realty Trust, Cboe Global Markets, Eagle Pharmaceuticals, and National Commerce — Fundamental Analysis, Key Performance Indications

2019-03-26 08:22:07 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-03-12 10:26:50 | See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.

2019-03-01 06:42:51 | Edited Transcript of EGRX earnings conference call or presentation 28-Feb-19 1:30pm GMT

2019-02-28 14:44:04 | Eagle Pharmaceuticals Inc EGRX Q4 2018 Earnings Conference Call Transcript

2019-02-28 06:50:00 | Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results